Company Filing History:
Years Active: 2023-2025
Title: Innovations by Guangchao Li in Antibody and CAR-T Cell Therapy
Introduction
Guangchao Li is a prominent inventor based in Guangdong, China. He has made significant contributions to the fields of biotechnology and cancer treatment through his innovative patents. With a total of 2 patents, his work focuses on enhancing therapeutic options for tumors.
Latest Patents
One of Guangchao Li's latest patents is the "Anti-CLL1 antibody and use thereof." This patent provides an anti-CLL1 antibody that demonstrates significant binding ability to both free and cell surface CLL1. The variable region of this antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. After humanization, the affinity of the antibody to CLL1 is further improved, showcasing its potential in clinical diagnosis and treatment of tumors.
Another notable patent is the "Use of chemokine receptor CXCR5." This disclosure presents a method for obtaining CAR-T cells with enhanced chemotaxis by modifying chimeric antigen receptor T cells (CAR-T cells) utilizing the chemotactic signal between CXCR5 and its ligand CXCL13. The chemokine receptor CXCR5 effectively guides CAR-T cells to migrate to tumors, enhancing their ability to clear tumor cells and addressing the challenges of existing CAR-T therapies for solid tumors.
Career Highlights
Guangchao Li is associated with Guangzhou Bio-gene Technology Co., Ltd., where he continues to advance his research and innovations. His work has the potential to significantly impact cancer treatment and improve patient outcomes.
Collaborations
Guangchao Li collaborates with notable colleagues, including Min Luo and Wen Ding, who contribute to his research endeavors.
Conclusion
Guangchao Li's innovative patents in antibody and CAR-T cell therapy highlight his commitment to advancing cancer treatment. His contributions are paving the way for more effective therapeutic options in the fight against tumors.